MPM Oncology Impact Management »

Zymeworks Del shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Zymeworks Del (ZYME) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Zymeworks Del

Tip: Access up to 7 years of quarterly data

All positions including Zymeworks Del held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Zymeworks Del by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $14M 565k 25.04

More positions owned by MPM Oncology Impact Management

DBV Technologies S A Sponsored Ads (DBVT)
Cullinan Therapeutics Common (CGEM)
Aktis Oncology Common
Liquidia Corporation Common (LQDA)
Alumis Common (ALMS)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Corcept Therapeutics Common (CORT)
Trevi Therapeutics Common (TRVI)
Dianthus Therapeutics Common (DNTH)
Xenon Pharmaceuticals Common (XENE)
MoonLake Immunotherapeutics Class A Ord (MLTX)
Travere Therapeutics Common (TVTX)
Evommune Common (EVMN)

View all positions for MPM Oncology Impact Management

Top funds holding Zymeworks Del

EcoR1 Capital
Rubric Capital Management
BlackRock
BVF
Perceptive Advisors
Morgan Stanley
Vanguard Group
Bnp Paribas Investment Partners
Vanguard Capital Management
Siren
Citadel Advisors
Dimensional Fund Advisors
Nextech Invest
State Street Corporation
Capricorn Fund Managers

View all funds holding Zymeworks Del